According to a new analysis, PLND does not impact recurrence-free survival but may reduce metastatic spread in intermediate- and high-risk prostate cancer. The benefit of PLND is most evident in ...

The role of pelvic lymph node dissection (PLND) in patients with localized prostate cancer remains controversial. Although guidelines are increasingly recommending extended PLND alongside radical ...

A phase I study of ADXS-504, a cancer type specific immunotherapy, for patients with biochemically recurrent prostate cancer. Background: The therapeutic benefit of pelvic lymph node dissection (PLND) ...

Fifteen-year outcomes of external radiation with or without 6 months of neoadjuvant deprivation therapy for intermediate risk prostate cancer. This is an ASCO Meeting Abstract from the 2025 ASCO ...

Clinical node involvement on preoperative PSMA-PET predicts radiographic recurrence for pN1 prostate cancer patients following RP/PLND.

Pelvic lymph node dissection is the only reliable method of staging for clinically localized prostate cancer. Despite the obvious prognostic advantages conferred by accurate staging, pelvic lymph node ...

68Ga-PSMA-11 PET scans have a 40% sensitivity for detecting pelvic nodal metastasis in men with intermediate- or high-risk prostate cancer, data show. Pelvic lymph node dissection still may be ...

Right Pelvic Lymphocele Investigators have explored various strategies to prevent lymphoceles from forming. Most prostatectomies are now being done with concomitant lymphadenectomy. A few factors are ...

At 7.3 years’ median follow-up, cabazitaxel failed to improve clinical PFS (62.8% vs 67.2%), metastasis-free survival, or overall survival versus androgen deprivation therapy plus radiotherapy.

Given the diagnostic challenge, a multidisciplinary team performed a radical hysterectomy, along with bilateral pelvic lymph ...